FTC weighs in on “no-authorised-generic” antitrust case
The US Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case that concerns a “no-authorised-generic” settlement between Teva and GlaxoSmithKline (GSK).
Allergan sues Aurobindo over eye drop generic
Allergan, along with Japan-based Senju and Kyorin have sued Indian pharma Aurobindo for infringing claims in the Japanese pharmaceutical companies’ reexamined US patent 6,333,045.
Bayer buys Merck’s consumer care arm for $14.2bn
Bayer AG has agreed to buy New Jersey-based Merck’s consumer care business for $14.2 billion, the companies announced today (May 6).
HGF promotes Nelson to partner
HGF has promoted Mike Nelson to partner. He joined the firm last year to work with the pharmaceutical and chemistry teams after arriving from AstraZeneca.
US hits out at Indian pharma patent protection
Patent protection in the pharmaceutical sector in India has raised “serious” concerns, the US government said yesterday, April 30, in its annual Special 301 Report.
Cephalon launches another Treanda action
Cephalon has filed another lawsuit to protect its chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma treatment Treanda (bendamustine hydrochloride), this time against Canadian pharmaceutical company Uman Pharma.
Actavis and Pfizer settle Celebrex litigation
Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).
AstraZeneca ‘has value’ says former Pfizer lawyer
AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.
Federal Circuit rules against Roche in Tamiflu case
The US Court of Appeals for the Federal Circuit has thrown out a lower court ruling that found Natco Pharma infringed a patent covering Roche’s flu drug Tamiflu (oseltamivir phosphate).
Pfizer criticises Indian pharma patent policy
Pfizer’s associate general counsel, Justin McCarthy, has sent a letter to India’s ambassador to the US, Subrahmanyam Jaishankar, urging the Indian government to “shift from using destructive IP policy as an access strategy,” according to reports.
